
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly's stock outlook is positively influenced by robust growth across several key business segments, with cardiovascular revenues increasing by 16.1% year-over-year in Q4, underscoring strong demand for its cardiometabolic products. The company's leadership in the electrophysiology market, highlighted by a remarkable 35% organic growth, positions it well for future expansion, especially with market forecasts predicting a 15% annual growth rate through 2026. Additionally, the neuromodulation segment also exhibited solid performance with a 10% year-over-year organic revenue increase, contributing to a diversified and resilient portfolio amidst an evolving healthcare landscape.
Bears say
Eli Lilly's stock outlook is negatively impacted by an 18% decline following guidance for 2026 that fell short of consensus expectations, compounded by perceived weaknesses in the Electrophysiology (EP) segment. Financial risks include potential pricing pressures, lackluster uptake of key products such as tirzepatide (Mounjaro), and higher debt levels stemming from recent mergers and acquisitions, which may hinder the company's operational leverage. Additionally, competition and potential underperformance in product launches further elevate the downside risks to Lilly's financial stability and growth trajectory.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares